The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Open accessAbstract
Acute intermittent porphyria (AIP) results from haploinsufficiency of porphobilinogen deaminase (PBGD), the third enzyme in the heme biosynthesis pathway. Patients with AIP have neurovisceral attacks associated with increased hepatic heme demand. Phenobarbital-challenged mice with AIP recapitulate the biochemical and clinical characteristics of patients with AIP, including hepatic overproduction of the potentially neurotoxic porphyrin precursors. Here we show that intravenous administration of human PBGD (hPBGD) mRNA (encoded by the gene HMBS) encapsulated in lipid nanoparticles induces dose-dependent protein expression in mouse hepatocytes, rapidly normalizing urine porphyrin precursor excretion in ongoing attacks. Furthermore, hPBGD mRNA protected against mitochondrial dysfunction, hypertension, pain and motor impairment. Repeat dosing in AIP mice showed sustained efficacy and therapeutic improvement without evidence of hepatotoxicity. Finally, multiple administrations to nonhuman primates confirmed safety and translatability. These data provide proof-of-concept for systemic hPBGD mRNA as a potential therapy for AIP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic potential of mRNA-based protein replacement therapies has also been tested in other metabolic disorders in preclinical studies, including hereditary tyrosinaemia type I (HTI)142, acute intermittent porphyria222,223, Fabry disease224,225, Crigler–Najjar syndrome type 1 (ref.226), α1 antitrypsin deficiency227, methylmalonic acidaemia/aciduria228, arginase deficiency229, citrin defic”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [222]
In the citing paper
“A recent preclinical study demonstrated that i.v. injection of human PBGD (hPBGD) mRNA encapsulated in MC3-based LNPs restored hepatic PBGD expression followed by a normalization of porphyrin precursor levels.[130]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [130]
In the citing paper
“In AIP mice, a single dose alleviated mitochondrial dysfunction, hypertension, and pain.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [130]
In the citing paper
“Importantly, the PBGD expression in the liver lasted for at least 10 days, which provided a full protection throughout the diseased period (5 to 7 days).[130]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [130]
Citations
Cites
Coding of facial expressions of pain in the laboratory mouse
Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E. D., Drummond, T. E., Echols, S., Glick, S., Ingrao, J. C., Klassen-Ross, T., LaCroix‐Fralish, M. L., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1455 · Cited by 1,570
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
Self-citationPuy, H., Gouya, L., & Deybach, J. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61925-5 · Cited by 727
Recommendations for the Diagnosis and Treatment of the Acute Porphyrias
Anderson, K. E., Bloomer, J. R., Bonkovsky, H. L., Kushner, J. P., Pierach, C. A., Pimstone, N. R., & Desnick, R. J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00010 · Cited by 622
Rogers, G. W., Brand, M. D., Petrosyan, S., Ashok, D., Elorza, Á. A., Ferrick, D. A., & Murphy, A. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021746 · Cited by 482
Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608634 · Cited by 399
Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α
Handschin, C., Lin, J. D., Rhee, J., Peyer, A., Chin, S., Wu, P., Meyer, U., & Spiegelman, B. M. (2005) · Cell · doi:10.1016/j.cell.2005.06.040 · Cited by 392
Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium
Bonkovsky, H. L., Maddukuri, V. C., Yazıcı, C., Anderson, K. E., Bissell, D. M., Bloomer, J. R., Phillips, J. D., Naik, H., Peter, I., Baillargeon, G. M., et al. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.06.036 · Cited by 264
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Self-citation
Research works printed but not linked: 1
- Fratz, E. J., Stojanovski, B. M., Ferreira G. C. in Handbook of Porphyrin Science Vol. 26 (eds Kadish, K. M. et al.) 3–78 (World Scientific Publishing, Hackensack, NJ, USA, 2014).
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
Metadata
- Authors
- Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., Benenato, K. E., Burke, K., Santamaría, E., Alegre, M., Pejenaute, Á., Kalariya, M., Butcher, W., Park, J.-S., Zhu, X., Sabnis, S., Kumarasinghe, E. S., Salerno, T., Kenney, M., Lukacs, C. M., Ávila, M. A., Martini, P. G. V., & Fontanellas, A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Instituto de Salud Carlos III (ES)
- Navarre Institute of Health Research (ES)
- Centro de Investigación Médica Aplicada (ES)
- Universidad de Navarra (ES)
- Corresponding author
- Martini, Paolo G. V.
- Fontanellas, Antonio
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 12
- Pages
- 1899-1909
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2895539268
- Cited by
- 181
- References
- 44
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 26 · 2023: 18 · 2022: 40 · 2021: 14 · 2020: 24 · 2019: 24 · 2018: 3
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- acute intermittent porphyria, porphobilinogen deaminase, hydroxymethylbilane synthase, mRNA therapeutics, lipid nanoparticles, gene therapy, heme biosynthesis, porphyrin precursors, mitochondrial dysfunction, hypertension, pain, motor impairment, non-human primates, hepatotoxicity
- MeSH terms
- Animals, Disease Models, Animal, Female, Heme, Humans, Liver, Male, Hydroxymethylbilane Synthase, RNA, Messenger, Genetic Therapy, Porphyria, Acute Intermittent, Hepatocytes, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
